Rocket Pharmaceuticals Inc
RCKT3.170USD
-0.060-1.86%
收盤 11/07, 16:00（美東）報價延遲15分鐘
343.02M總市值
虧損本益比TTM
關於 Rocket Pharmaceuticals Inc 公司
Rocket Pharmaceuticals, Inc. 是一家完全整合的後期生物技術公司。該公司正在推進一系列可持續的試驗性基因療法，旨在糾正複雜和罕見疾病的根本原因。其基於慢病毒 (LV) 載體的基因療法針對血液病，包括針對範康尼貧血症（一種難以治療的遺傳病，會導致骨髓衰竭和潛在的癌症）、白細胞粘附缺陷-I (LAD-I)（一種嚴重的兒科遺傳病，會導致反覆發作且危及生命的感染，這些感染通常是致命的）和丙酮酸激酶缺陷 (PKD)（一種單基因紅細胞疾病，導致紅細胞破壞增加和輕度至危及生命的貧血）的後期項目。該公司還有兩個臨牀階段和一個臨牀前階段的體內腺相關病毒 (AAV) 項目，包括針對 Danon 病、Plakophilin-2 致心律失常性心肌病和 BAG3 擴張型心肌病的項目。
Rocket Pharmaceuticals Inc簡介
公司代碼RCKT
公司名稱Rocket Pharmaceuticals Inc
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
員工數量299
證券類型Ordinary Share
年結日Feb 18
公司地址9 Cedarbrook Drive
城市CRANBURY
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編08512
電話16464409100
網址https://www.rocketpharma.com/
公司代碼RCKT
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
Rocket Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
60.82K
-32.22%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Independent Director
Independent Director
40.00K
+33.33%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Independent Director
Independent Director
30.00K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
30.00K
--
Mr. Piratip Pratumsuwan
Mr. Piratip Pratumsuwan
Independent Director
Independent Director
30.00K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
60.82K
-32.22%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 14 小時前
更新時間: 14 小時前
持股股東
股東類型
持股股東
持股股東
佔比
RTW Investments L.P.
16.39%
Maverick Capital, Ltd.
7.75%
The Vanguard Group, Inc.
6.37%
BlackRock Institutional Trust Company, N.A.
5.89%
Suvretta Capital Management, LLC
3.84%
其他
59.76%
持股股東
持股股東
佔比
RTW Investments L.P.
16.39%
Maverick Capital, Ltd.
7.75%
The Vanguard Group, Inc.
6.37%
BlackRock Institutional Trust Company, N.A.
5.89%
Suvretta Capital Management, LLC
3.84%
其他
59.76%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
29.89%
Hedge Fund
28.47%
Investment Advisor
23.23%
Research Firm
6.15%
Individual Investor
3.80%
Bank and Trust
0.28%
Venture Capital
0.14%
Pension Fund
0.13%
Family Office
0.04%
其他
7.88%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
493
95.29M
88.31%
-15.26M
2025Q2
493
101.52M
94.23%
-15.02M
2025Q1
494
114.28M
106.44%
-9.69M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RTW Investments L.P.
17.69M
16.39%
--
--
Sep 19, 2025
Maverick Capital, Ltd.
8.36M
7.75%
+2.82M
+50.78%
Jun 30, 2025
The Vanguard Group, Inc.
6.10M
5.65%
-502.58K
-7.61%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.35M
5.89%
+202.53K
+3.29%
Jun 30, 2025
Suvretta Capital Management, LLC
4.14M
3.84%
+641.33K
+18.31%
Jun 30, 2025
MPM BioImpact LLC
3.90M
3.62%
+2.28M
+141.19%
Jun 30, 2025
Two Sigma Investments, LP
3.23M
2.99%
+3.23M
--
Jun 30, 2025
Millennium Management LLC
2.35M
2.18%
+1.60M
+214.37%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.03M
1.88%
+36.85K
+1.85%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.02M
1.87%
+241.77K
+13.57%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
WisdomTree BioRevolution Fund
0.4%
Global X Genomics & Biotechnology ETF
0.37%
Invesco Nasdaq Biotechnology ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.77%
WisdomTree BioRevolution Fund
佔比0.4%
Global X Genomics & Biotechnology ETF
佔比0.37%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
Fidelity Enhanced Small Cap ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
